论文部分内容阅读
目的 :探讨胃癌ras其因突变及其蛋白P2 1过表达的临床病理学意义。方法 :应用SP免疫组化及PCR -SSCP两种方法检测 66例胃癌标本及其癌旁组织 (有不同程度的肠化和异型增生 )。结果 :P2 1在癌组织阳性率为 5 1 5 % ,癌旁组织 69 7% ,P2 1阳性与肿瘤患者性别、年龄无明显关系 ;但与癌细胞分化 ,癌细胞浸润组织深度、淋巴结转移显著相关 (P <0 0 5 )。胃癌组织ras12 /13基因突变 2例 ,同时伴P2 1过表达。结论 :ras基因突变P2 1过表达与胃癌发生有关 ,其阳性患者预后不良 ,提示对胃癌患者P2 1阳性者加强术后综合治疗。
Objective: To investigate the clinicopathological significance of ras mutation and its protein P2 1 overexpression in gastric cancer. Methods: Sixty-six gastric cancer specimens and their adjacent tissues (with varying degrees of intestinal metaplasia and dysplasia) were detected by SP immunohistochemistry and PCR-SSCP. Results: The positive rate of P2 1 was 51.5% in cancer tissues and 69.7% in adjacent tissues. There was no significant correlation between the positive rate of P2 1 and the gender and age of cancer patients. However, with the differentiation of cancer cells, the depth of cancer cell infiltration and lymph node metastasis Related (P <0 05). Two cases of gastric cancer ras12 / 13 gene mutation accompanied with P2 1 overexpression. Conclusion: The overexpression of ras gene P2 1 is associated with the development of gastric cancer, and its positive prognosis is poor. It suggests that postoperative comprehensive treatment of patients with P2 1 positive gastric cancer should be strengthened.